Unveiling the roles of HBV polymerase for new antiviral strategies

Daniel N. Clark, Jianming Hu

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.

Original languageEnglish (US)
Pages (from-to)283-295
Number of pages13
JournalFuture Virology
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

Antiviral Agents
RNA-Directed DNA Polymerase
RNA-Binding Proteins
DNA
RNA Stability
Viral RNA
Product Packaging
Enzymes
Infection
Hepatocellular Carcinoma
Fibrosis
Hepatitis B virus P protein
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

@article{67df2533d85e4529bdb6b5aa9da4d418,
title = "Unveiling the roles of HBV polymerase for new antiviral strategies",
abstract = "Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.",
author = "Clark, {Daniel N.} and Jianming Hu",
year = "2015",
month = "3",
day = "1",
doi = "10.2217/fvl.14.113",
language = "English (US)",
volume = "10",
pages = "283--295",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "3",

}

Unveiling the roles of HBV polymerase for new antiviral strategies. / Clark, Daniel N.; Hu, Jianming.

In: Future Virology, Vol. 10, No. 3, 01.03.2015, p. 283-295.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Unveiling the roles of HBV polymerase for new antiviral strategies

AU - Clark, Daniel N.

AU - Hu, Jianming

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.

AB - Infection with HBV is common worldwide, with over 350 million chronic carriers. Chronic HBV infection is associated with cirrhosis and hepatocellular carcinoma. All currently available oral antivirals are directed against the HBV polymerase enzyme, a reverse transcriptase. HBV polymerase contains several important domains and motifs which define its functions and reveal ways to further target it. This enzyme executes many functions required for the HBV replication cycle, including viral RNA binding, RNA packaging, protein priming, template switching, DNA synthesis and RNA degradation. In addition, HBV polymerase must interact with host proteins for its functions. Future therapeutics may inhibit not only the DNA synthesis steps which are carried out by the reverse transcriptase domain (as all current antivirals do) but other domains, functions and interactions which are essential to the HBV replication cycle.

UR - http://www.scopus.com/inward/record.url?scp=84925174803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925174803&partnerID=8YFLogxK

U2 - 10.2217/fvl.14.113

DO - 10.2217/fvl.14.113

M3 - Review article

C2 - 25893003

AN - SCOPUS:84925174803

VL - 10

SP - 283

EP - 295

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 3

ER -